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Abstract In our previous studies, CB1 cannabinoid receptor
agonists stimulated production of cyclic GMP and translo-
cation of nitric oxide (NO)-sensitive guanylyl cyclase in
neuronal cells (Jones et al., Neuropharmacology 54:23–30,
2008). The purpose of these studies was to elucidate the
signal transduction of cannabinoid-mediated neuronal nitric
oxide synthase (nNOS) activation in neuronal cells.
Cannabinoid agonists CP55940 (2-[(1S,2R,5S)-5-hydroxy-
2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)
phenol), WIN55212-2 (R(+)-[2,3-dihydro-5-methyl-3-
[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-
(1-naphthalenyl)methanone mesylate), and the metabolically
stable analog of anandamide, (R)-(+)-methanandamide
stimulated NO production in N18TG2 cells over a 20-min
period. Rimonabant (N-(piperidin-lyl)-5-(4-chlorophenyl)-
1-(2,4-dichlorophenyl)-4-methyl-H-pyrazole-3-carboxamide),
aC B 1 receptor antagonist, partially or completely curtailed
cannabinoid-mediated NO production. Inhibition of NOS
activity (N
G-nitro-L-arginine) or signaling via Gi/o protein
(pertussis toxin) significantly limited NO production by
cannabinoid agonists. Ca
2+ mobilization was not detected in
N18TG2 cells after cannabinoid treatment using Fluo-4 AM
fluorescence. Cannabinoid-mediated NO production was
attributed to nNOS activation since endothelial NOS and
inducible NOS protein and mRNA were not detected in
N18TG2 cells. Bands of 160 and 155 kDa were detected on
Western blot analysis of cytosolic and membrane fractions of
N18TG2 cells, using a nNOS antibody. Chronic treatment of
N18TG2 cells with cannabinoid agonists downregulated
nNOS protein and mRNA as detected using Western blot
analysis and real-time polymerase chain reaction, respec-
tively. Cannabinoid agonists stimulated NO production via
signaling through CB1 receptors, leading to activation of Gi/o
protein and enhanced nNOS activity. The findings of these
studies provide information related to cannabinoid-mediated
NO signal transduction in neuronal cells, which has important
implications in the ongoing elucidation of the endocanna-
binoid system in the nervous system.
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Introduction
Nitric oxide (NO) is a highly reactive compound that can
serve as a beneficial physiologic messenger or as a toxin in
disease processes in various tissues (Schmidt and Walter
1994). NO is generated from L-arginine by oxidation–
reduction reactions catalyzed by one of at least three iso-
forms of nitric oxide synthase (NOS), namely the neuronal
(nNOS), endothelial (eNOS), and inducible (iNOS) iso-
forms (Alderton et al. 2001; Boucher et al. 1999; Knowles
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enzymes, whereas pro-inflammatory mediators induce the
iNOS activity and gene expression. NO stimulates physi-
ologic and pathophysiologic effects in neurons of the
central and peripheral nervous systems (Christopherson
and Bredt 1997). NO modulates neuronal function through
release of neurotransmitters and regulation of excitability
and firing in long-term depression, long-term potentiation,
and memory processes of synaptic plasticity (Holscher
1997; Huang 1997; Ohkuma and Katsura 2001; Prast
and Philippu 2001; Wang, et al. 2005). Elevation of NO
production has also been associated with several neuro-
logical diseases such as Parkinson’s disease, Alzheimer’s
disease, multiple sclerosis, and stroke (Duncan and Heales
2005). Many of the effects of excessive NO production
have been described as detrimental. In contrast, it was shown
that hyperphosphorylation, truncation, and aggregation of
Tau protein were increased in an Alzheimer’s disease model
bred on an iNOS knockout mouse background (Colton
et al. 2006), implicating a protective role for NO in the
pathogenesis of this disease.
Endogenous and exogenous cannabinoids mediate their
effects though activation of G-protein coupled receptors
called CB1 and CB2 cannabinoid receptors (Palmer et al.
2002). CB1 cannabinoid receptors have been found in brain
and other nervous tissue, whereas CB2 receptors have been
detected mainly in immune cells and tissues (Howlett et al.
2002). CB1 receptors and NOS have been closely associ-
ated in striatal (Fusco et al. 2004) and spinal cord (Salio
et al. 2002) neurons. Activation of cannabinoid receptors
by the endocannabinoid, anandamide, in the median
eminence led to NO production, which could be curtailed
by inhibition of NOS activity by L-N-arginine-methyl ester
(L-NAME; Prevot et al. 1998). NO signaling has been
shown to be involved in cannabinoid-mediated hypothermia
and catalepsy (Azad et al. 2001). Furthermore, co-treatment
of rats with L-NAME and WIN55212-2 enhanced hypo-
thermia through a synergistic effect (Rawls et al. 2004). In
chronic treatment experiments, repeated dosing of L-NAME
inhibited the development of tolerance to the hypothermic
and cataleptic effects of WIN55212-2 (Spina et al. 1998).
Cannabinoids have been shown to protect against N-methyl-
D-aspartate (NMDA) receptor-mediated neurotoxicity of
retinal (El-Remessy et al. 2003) and cerebrocortical (Kim
et al. 2006) neurons; these pathologic effects were believed
to involve elevated NO production and generation of
reactive nitrogen species (El-Remessy et al. 2003; Rameau
et al. 2003; Rameau et al. 2007).
In our previous studies, cannabinoid agonists stimulated
production of cyclic GMP and translocation of NO-sensitive
guanylyl cyclase in neuronal cells (Jones et al. 2008). Signal
transduction mechanisms and all subsequent downstream
effects of cannabinoid-mediated NO production in neuronal
cells have yet to be described. The purpose of these studies
is to elucidate signal transduction mechanisms of the
cannabinoid-mediated nNOS activation resulting in NO
production in neuronal cells.
Materials and methods
Materials
The reagents were purchased from Sigma Chemical
Company (St. Louis, MO, USA), unless otherwise stated.
CP55940 (2-[(1S,2R,5S)-5-hydroxy-2-(3-hydroxypropyl)
cyclohexyl]-5-(2-methyloctan-2-yl)phenol) and rimonabant
(N-(piperidin-lyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-
4-methyl-H-pyrazole-3-carboxamide) were provided by the
National Institute on Drug Abuse drug supply program.
WIN55212-2 (R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)
methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)
methanone mesylate), (R)-(+)-methanandamide (MetAEA),
and 2-arachidonoylglycerol were purchased from Tocris
Cookson (Ellison, MO, USA). N
G-nitro-L-arginine (L-NNA)
and N
G-nitro-D-arginine (D-NNA) were purchased from
EMD Chemicals (Gibbstown, NJ, USA). NO indicator 4-
amino-5-methylamino-2′,7′-difluorofluorescein diacetate,
nuclear stain 4,6-diamidino-2-phenylindole dihydrochloride,
Fluo-4 AM, and Prolong Antifade Mounting Media were pur-
chased from Molecular Probes (Eugene, OR, USA). Compo-
nentsofCytomix;humanrecombinanttumornecrosisfactor-α
(TNF-α;1 . 1 × 1 0
5 units/mg protein); interleukin-1β (IL-1β;
2×0
5 units/mg); and interferon-γ (IFNγ;2 ×10
4 units/mg)
were purchased from R&D Systems (Minneapolis, MN,
USA). Acrylamide, N,N,N′,N′-tetramethylethylene diamine,
sodium dodecylsulfate (SDS), and polyvinylidine difluoride
membranes were from BioRad Laboratories (Hercules, CA,
USA). The nNOS rabbit polyclonal antibody (catalog no.
160870) was purchased from Cayman Chemical (Ann Arbor,
MI, USA). Antibodies used to detect iNOS (mouse mono-
clonal IgG1 (catalog no. 610309)) and eNOS (mouse
monoclonal IgG1 (catalog no. 610297)) were purchased from
Transduction Laboratories (Lexington, KY, USA). Goat anti-
rabbit IgG horseradish peroxidase (catalog no. G21234) and
goat anti-mouse IgG horseradish peroxidase (catalog no.
G21040) were purchased from Biosource International
(Camarillo, CA, USA). Goat and mouse sera were from
Gibco Life Technologies (Gaithersburg, MD, USA). Rainbow
molecular markers and Enhanced Chemiluminescence Detec-
tion kit were from Amersham Biosciences (Piscataway, NJ,
USA). The RNeasy Mini purification kit was from Qiagen
(Valencia, CA, USA). The GeneAmp Gold RNA polymerase
chain reaction (PCR) Core kit, TaqMan Universal PCR
Master Mix, and Assays-on-Demand Gene Expression Assay
mixes specific for mouse 18S ribosomal RNA, nNOS, iNOS,
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USA). Primers for amplification of nNOS, iNOS, and eNOS
were from Invitrogen (Carlsbad, CA, USA), and 18S
ribosomal RNA primers were acquired from Amplicon
(Pullman, WA, USA).
Cell culture
N18TG2 neuroblastoma cells (passage numbers 25–50) were
maintained at 37°C under a 5% CO2 atmosphere in
Dulbecco’s modified Eagle’sm e d i u m / H a m ’s F-12 (1:1) with
GlutaMax, sodium bicarbonate, and pyridoxine–HCl, sup-
plemented with penicillin (100 units/ml) and streptomycin
(100 μg/ml; Gibco Life Technologies) and 10% heat-
inactivated bovine serum (JH Bioscience, Lenexa, KS,
USA). An aliquot of drug stocks (stored at −20°C as
10 mM solutions in ethanol) or ethanol (control) was air-
dried under sterile conditions in trimethylsilyl-coated glass
test tubes and taken up in 100 volumes of 5 mg/ml fatty
acid-free bovine serum albumin and serially diluted before
being added (100 μl) to 75 cm
2 flasks containing 10 ml of
media. Where indicated, N18TG2 cells were pretreated
with the CB1 antagonist rimonabant (1 μM) for 30 min
prior to addition of agonists or at the times indicated before
harvesting. Pertussis toxin (100 ng/ml final concentration;
BIOMOL, Plymouth Meeting, PA, USA) was added to
flasks containing fresh media 16 h before addition of
agonists.
Measurement of NO production
NO production was measured using previously described
methods (McCollum et al. 2007). Briefly, the cells were
grown until 85% confluent on 12 mm uncoated glass cover
slips in 24-well plates. The cells were loaded with 5 μM4 -
amino-5-methylamino-2′,7′-difluorofluorescein (DAF-FM)
diacetate (cell permeable form of DAF-FM) for 1 h in
physiological saline solution (PSS; 150 mM NaCl, 5.4 mM
KCl, 1.18 mM Na2HPO4, 1.17 mM MgSO4, 6.0 mM
NaHCO3, 5.5 mM dextrose, 1 mM CaCl2,2 0m MN a
HEPES, pH 7.4). The cells were washed with PSS and
treated for 20 min with cannabinoid agonists CP55940,
WIN55212-2, or MetAEA in PSS. Intracellular DAF-FM
diacetate is metabolized to DAF-FM, which combines with
NO to produce a fluorescent benzotriazole derivative
(Kojima et al. 1998) that when excited at 495 nm, emits
light at 515 nm in direct proportion to the NO inside the
cells. The cells were washed with phosphate-buffered saline
(PBS; 138 mM NaCl, 5.4 mM KCl, 1.07 Na2HPO4,
1.1 mM KH2PO4, 15 mM Na HEPES, pH 7.4) and fixed
with 0.5% glutaraldehyde in PBS at 4°C for 10 min, and
nuclei were labeled with DAPI (Sugimoto et al. 2000;
Takumida and Anniko 2001). Autofluorescence was
minimized with 0.1% Na borohydride, which reduced
spurious aldehyde combining with amines or proteins
leading to background fluorescence (Clancy and Cauller
1998). The inverted cover slips were mounted onto glass
slides using ProLong Antifade, and images from the slides
were digitalized using identical exposure time and bright-
ness settings for all conditions using a Nikon Eclipse E600
fluorescence microscope (Nikon Instruments, Melville,
NY, USA). Quantitation of fluorescence was performed
using Image Pro Plus 4.5 Software (Media Cybernetics,
Bethesda, MD, USA). Ratios of green (NO-DAF-FM) to
blue (DAPI) fluorescence were tabulated from three images
of fields containing 15 or more cells, and the ratios were
normalized to vehicle control=1 for each experiment
(McCollum et al. 2007).
Reverse transcriptase-polymerase chain reaction
Following RNA isolation and quantitation, 1 μg of RNA
from each sample was reverse-transcribed according to the
manufacturer’s specifications of the GeneAmp Gold RNA
PCR Core kit. The resulting cDNA was amplified
(35 cycles, AmpliTaqGold DNA polymerase and GeneAmp
Gold kits) using primers described in previous studies to
identify NOS isozymes (Dodd et al. 2000) and 18S ribo-
somal RNA as the loading control (28 cycles; Goidin et al.
2001). PCR products were detected from agarose gels
(1.6%) after electrophoresis in TBE buffer containing
50 ng/ml ethidium bromide.
Real-time quantitative polymerase chain reaction (qPCR)
Total RNA was extracted from N18TG2 cells and purified
using the Qiagen RNeasy Mini Kit, and purity was
determined spectrophotometrically using the 260/280 ratio.
Total RNA (1 μg) was reversed-transcribed into cDNA using
random hexamers using the Applied Biosystems cDNA
Archive Kit. Quantitative polymerase chain reaction (qPCR)
reactions were performed using TaqMan Universal PCR
Master Mix and Applied Biosystems gene expression assays
(25 μl volumes) using an Applied Biosystems 7500 Real-
time PCR System. Ribosomal 18S RNA was the reference
standard gene, and relative quantitation was determined
using the ΔΔCt method (Livak and Schmittgen 2001).
Western blot analysis
After treatment, N18TG2 cells were harvested with PBS-
EDTA (2.7 mM KCl, 138 mM NaCl, 10.4 mM glucose,
1.5 mM KH2PO4, 8 mM Na2HPO4, 0.625 mM EDTA,
pH 7.4). The cells were suspended in cold TME buffer
(20 mM Tris–Cl, pH 7.4, 3 mM MgCl2, 1 mM Na EDTA)
with a protease inhibitor cocktail (set III, catalog no. 59134,
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inhibit aspartic, cysteine, serine, and aminopeptidases. The
cells were allowed to swell in the hypotonic solution
(15 min) and then were homogenized with a glass–glass
homogenizer and centrifuged at 1,000×g at 4°C for 10 min.
The pellet (nuclear and cellular debris) was discarded, and
the supernatant was centrifuged at 100,000×g for 30 min at
4°C. The membranes were resuspended in 1/20 the cytosol
volume of 50 mM Tris–Cl buffer, pH 7.4, and aliquots of
supernatant and membranes were stored at −80°C.
Rat forebrain cytosolic fractions were prepared from
frozen whole rat brains purchased from Pel-Freeze (Rogers,
AK, USA). The brains were thawed in ice-cold SME
solution (320 mM sucrose, 5 mM MgCl2, 2 mM Tris–
EDTA). The brain tissue was homogenized in a glass–glass
homogenizer in 2 ml of SME per gram of tissue and
centrifuged at 1,000×g at 4°C for 10 min. The pellet was
resuspended in 1 ml of SME for a second centrifugation,
and the combined supernatants were centrifuged at
39,000×g at 4°C for 25 min. The cytosolic fractions were
stored in aliquots at −80°C until use. The protein concen-
trations were determined using the Coomassie dye binding
method (Bradford 1976).
Protein fractions were taken up in Laemmli’s sample
buffer with 1 mM dithiotheitol and heated at 60°C for
10 min, and equal amounts of protein (45 μg) were loaded
per lane on SDS-6% polyacrylamide gels for electrophore-
sis (50 V for 30 min and then 120 V for 80 min). The
proteins were transferred onto polyvinylidine difluoride
membranes in Towbin’s buffer (24 mM Tris Base, 192 mM
glycine, 20% methanol, pH 8.3) for 1 h in the cold at 95 V
using a Bio-Rad Trans-Blot Cell (BioRad Laboratories)
with an ice pack. Blots were rinsed three times (5 min each)
with Tris-buffered saline (TBS; 20 mM Tris–Cl, pH 7.4,
137 mM NaCl) and incubated with blocking solution (5%
nonfat dry milk, 5% goat serum in TBS) at room
temperature for 1 h. Blots were then incubated for 1 h at
room temperature with an antibody (1:1,000) raised against
a peptide comprising amino acids 1422–1433 of human
nNOS (Bredt et al. 1991; Nakane et al. 1993) or amino
acids 1418–1429 of mouse nNOS (Ogura et al. 1993). The
blots were washed three times with TBS-T (TBS containing
0.1% Tween 20), incubated with horseradish peroxidase-
coupled anti-rabbit IgG (1:8,000) for 1 h at room
temperature, and washed five times with TBS-T followed
by five times with NANOpure water. Immunoreactive
bands were detected by enhanced chemiluminescence and
exposure to Hyperfilm at various time intervals to obtain
optimal signals. The blots were developed using a Kodak
M35A X-OMAT processor (Rochester, NY, USA). Band
densities were quantified using an Alpha Innotech Imager
with AlphaEase software (Alpha Innotech, San Leandro,
CA, USA). The average number of pixels per enclosed area
after background correction was normalized to the control
samples as 100%. The data were tested for statistically
significantdifferences using one-way ANOVA andDunnett’s
post hoc test or Student’s t test (Prism version 4.00,
GraphPad Software, San Diego, CA, USA).
Calcium imaging
N18TG2 cells were cultured on 25-mm glass cover slips in
six-well plates for 48 h until 85% confluent. The cover slips
were mounted in an Attofluor Cell Chamber (catalog no.
A-7816, Molecular Probes). Cells were loaded with 5 μM
Fluo-4 AM at room temperature, and the cover slips were
washed three times with PSS before exposure to agonists.
One milliliter of PSS was maintained in the chamber
throughout the experimental period by removing 100 μlo f
PSS before each addition of 100 μl of cannabinoid agonists
(0.3 nM–1 μM, final concentration). Serially increasing
concentrations of agonists were added to the chamber every
60 s over a time course of 360 s. Intracellular Ca
2+ mea-
surements were taken from images containing up to 40 cells
and captured at a rate of one frame per 983 ms, using a
Zeiss LSM 510 Confocal microscope with LSM 510
software (Zeiss, Thornwood, NY, USA). Excitation and
emitting wavelengths were 488 and 514 nm, respectively.
The baseline was established as the fluorescence at the
initial 30 s prior to adding drugs. For every experiment, the
effects of cannabinoid agonists were compared to the dose-
dependent response to bradykinin. The data were analyzed,
and graphs were prepared using Prism 4.00.
Results
CB1 agonists stimulate NO production in N18TG2 cells
N18TG2 neuroblastoma cells loaded with DAF-FM-
diacetate were treated with cannabinoid receptor agonists
CP55940, WIN55212-2, and the metabolically stable anan-
damide analog MetAEA (Fig. 1a). The low background
fluorescence indicates that the cellular production of NO
does not occur constitutively in these cells. Over the 20-min
period of NO accumulation, all three cannabinoid receptor
agonists produced maximal NO-DAF-FM fluorescence
at 10 nM concentrations, indicating that the cells were
extremely sensitive to agonist stimulation (Fig. 1b). Pre-
treatment with the CB1 antagonist rimonabant reduced the
NO-DAF-FM fluorescence in response to 10 nM CP55940
or WIN55212-2 and 1 μM MetAEA to the unstimulated
control levels (Fig. 1c), indicating that the NO production
could be attributed to CB1 receptor stimulation. Previous
studies had demonstrated that the CB2 receptor is not
expressed in N18TG2 cells (Jones et al. 2008), thereby
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acting on the CB2 receptor. The observation that NO-DAF-
FM fluorescence could not be reduced to background at
1 μM can be explained by the antagonist competition
against a supra-maximal agonist concentration. Rimonabant
did not independently impact the fluorescence of NO-DAF-
FM, indicating that the CB1 receptor does not exhibit
constitutive activity to produce NO in these cells.
Mobilization of Ca
2+ was determined in analysis of its
role in cannabinoid-mediated NO production. Treatment of
N18TG2 cells with endocannabinoid 2-arachidonoylglycerol
and synthetic CB1 receptor agonists CP55940 and
WIN55212-2 did not mobilize Ca
2+ in comparison to the
effects of bradykinin (Fig. 2). These results suggest alterna-
tive signaling pathways for cannabinoid-mediated NO
production other than through Ca
2+ mobilization.
nNOS is responsible for the NO production
MetAEA-stimulated NO-DAF-FM fluorescence was atten-
uated by L-NNA, a non-selective NOS inhibitor, whereas
the poorly active isomer D-NNA was not effective (Fig. 3).
L-NNA similarly reduced NO-DAF-FM fluorescence
Fig. 1 Cannabinoids stimulate
nitric oxide (NO) production in
N18TG2 cells. a Cells were
treated with vehicle (a), 1 μM
CP55940 (b), WIN55212-2 (c),
or methanandamide (d) for
20 min. NO production was
detected from fluorescence of
NO-DAF-FM (bar=100 μm).
b Agonist log dose-response
studies. N18TG2 cells were
treated with the indicated
concentrations of cannabinoid
agonists (squares CP55940,
inverted triangles WIN55212-2,
triangles methanandamide). NO
accumulation (20 min) in the
cells was quantitated as the
DAF-FM (DAF)/DAPI fluores-
cence intensity ratios mean±
SEM from N=3 independent
experiments. Statistically
different from control
(C;* p<0.01). c CB1 antagonist
on NO production by N18TG2
cells. Cells were pre-incubated
(30 min) with 1 μM rimonabant
(RIM) or vehicle (Veh) and
subsequently treated (20 min)
with Veh or 0.01 or 1 μM
CP55940 (CP), WIN55212-2
(WIN), or methanandamide
(MetAEA). Values are signifi-
cantly different from agonist
alone (*p<0.01, **p<0.05)
Fig. 2 Ca
2+ mobilization in N18TG2 cells: cannabinoid agonists
compared with bradykinin. N18TG2 cells loaded with 5 μM Fluo-
4 AM were treated with 2-arachidonoylglycerol (2-AG), CP55940,
WIN55212-2, or bradykinin (BK) at the indicated concentrations and
fluorescence intensity evaluated using confocal microscopy. Data
denote the percentage of total cells fluorescing above baseline over a
6-min experimental period and are presented as the mean±SEM from
N=5–9 experiments
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Other inhibitors, including 1-amino-2-hydroxyguanidine
para-toluenesulfonate, 7-nitroindazole, S-methylisothiourea
sulfate, and L-thiocitrulline (a constitutive NOS inhibitor)
also attenuated NO-DAF-FM fluorescence in response to
CB1 agonists (Carney and Norford, data not shown).
Because of the relatively poor selectivity exhibited by
NOS inhibitors, the question of which NOS type was
responsible for the NO production was addressed using
protein and gene expression studies. As shown in Fig. 4a,
antibodies staining for nNOS readily identified two bands
on 6% polyacrylamide SDS-PAGE that are within the size
range described previously by others (Grant et al. 2002;
Putzke et al. 2000). Identical band patterns were detected in
membrane-bound and 100,000×g cytosolic proteins from
N18TG2 cells. The two bands may be representative of the
expression of nNOS splice variants (Boissel et al. 1998;
Wang et al. 1999) or post-translational modifications
(Rameau et al. 2007). In contrast, there was no detectable
eNOS found in the N18TG2 preparations on Western blots
under conditions in which eNOS from human vascular
endothelial cells could readily be observed (Fig. 4b). iNOS
protein was not found in N18TG2 preparations, although
iNOS could be detected among brain cytosolic proteins
(Fig. 4c). In order to determine if an inflammatory stimulus
could induce iNOS, cells were treated with TNF-α,I L - 1 β,
and IFN-γ (10 ng/ml of each cytokine, Cytomix) for 8 to
20 h. In no experiment did we observe an induction of
iNOS using conditions in which RAW 264.7 cells
responded with a robust increase in iNOS protein (Norford
et al. 1998).
In order to determinelevelsof gene expressionof thethree
NOS isoforms, total RNA was isolated, and cDNA was
amplified using previously published primers designed to
detect expression of nNOS, eNOS, and iNOS genes (Dodd et
al. 2000). Analysis by PCR indicated the expression of
nNOS, but not eNOS or iNOS (Fig. 4d). cDNA prepared
using the random primer method and quantified by qPCR
also indicated that nNOS is expressed, whereas eNOS and
iNOS were either undetectable or at the limits of detectabil-
ity by this method (data not shown).
CB1-stimulated NO production requires Gi/o proteins
CB1 receptors activate Gi/o proteins, which have been
implicated in the inhibition of adenylyl cyclase or stimula-
tion of mitogen activated protein kinase phosphoryation
(Mukhopadhyay et al. 2002). To test whether nNOS acti-
Fig. 3 Endocannabinoid-
stimulated NO accumulation
antagonized by a NOS inhibitor.
a N18TG2 cells were treated
with a methanandamide
(MetAEA) alone (1 μM) or b
following pretreatment with
NOS inhibitor N
G-nitro-L-
arginine (L-NNA;1μM; bar=
100 μm). b Quantitation of
effects of NOS inhibitor L-NNA
and its inactive enantiomer N
G-
nitro-D-arginine (D-NNA;1μM)
on methanandamide-stimulated
NO accumulation in N18TG2
cells. Data are presented as the
DAF/DAPI fluorescence inten-
sity ratio (mean±SEM from N=
3 independent experiments).
Values significantly different
from those of MetAEA-
stimulated cells (*p<0.01)
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pertussis toxin, which ADP-ribosylates a cys residue on Gi/o
family proteins that is critical for functional interaction with
GPCRs. After Gi/o inactivation, CP55940, WIN55212-2, or
MetAEA at >10-fold their maximal concentrations were
not able to elicit stimulation above basal (Fig. 5), implicating
Gi/o protein signaling as a requisite step to NO production.
Cellular levels of nNOS protein (both 160 and 155 kDa
bands) were significantly decreased by treatment with
prolonged incubation with WIN55212-2 (1 to48 h),although
the decline in response to CP55940 was not statistically
significant (Figs. 6a and b). The decrement in nNOS protein
was observed in both the cytosolic fraction as well as the
membranes. nNOS mRNA was decreased at 8 and 24 h,
with WIN55212-2 eliciting the most robust depletion of
mRNA (Fig. 6c).
Discussion
The CB1 receptor and nNOS protein have been identified in
close proximity in brain areas suggestive of functional
interactions that may be of importance in a variety of
physiological states in which NO could serve either a
paracrine or autocrine function. It has been shown that CB1
receptor and nNOS are co-localized in neurons in lamina II
and X regions of the spinal cord (Salio et al. 2002). In
striatal medium spiny neurons, CB1 receptors coexist on at
least one third of the nNOS-expressing neurons (Azad et al.
2001; Fusco et al. 2004). In the hypothalamic preoptic area
and arcuate nucleus, NOS and CB1 receptors interact in
thermoregulation (Rawls et al. 2004) and gonadotrophin-
releasing hormone release (Prevot et al. 1998). In the
hippocampus, the α1β1 isoform of NO-sensitive guanylyl
d
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Fig. 4 NOS isozymes detected in N18TG2 cells. a Western blot
analysis of nNOS in membrane and cytosolic fractions from N18TG2
cells is depicted. The 100,000×g cytosolic and the membrane fractions
(45 μg) were subjected to SDS-PAGE (6% polyacrylamide) and
stained with antisera (Cayman Chemicals) that recognizes nNOS
protein. Blots are representative of at least three independent experi-
ments. b Membrane fractions of human umbilical vein endothelial
cells (HUVEC; 20 μg) and N18TG2 cells (45 μg) were separated by
SDS-PAGE, and proteins were stained with an eNOS antibody. Band
densitometry is normalized to eNOS levels in HUVEC cells as 100%
(mean, N=3 experiments). c Cytosolic fractions of rat brain (7 μg) and
Cytomix-treated N18TG2 cells (45 μg) were subjected to SDS-PAGE,
and proteins were stained with an iNOS antibody. Band densitometry
is normalized to iNOS in rat brain as 100% (mean, N=3 experiments).
d Gel composite of PCR products denoting expression of nNOS,
iNOS and eNOS genes by N18TG2 (N18) cells compared to a DNA
marker (M). Western blot and PCR analyses of nNOS, iNOS, and
eNOS protein and genes, respectively, are representative of three
independent experiments
344 J Neuroimmune Pharmacol (2009) 4:338–349cyclase was localized to the presynaptic CCK-positive
(68%) GABAergic terminals (Szabadits et al. 2007), which
has been co-expressed with the majority of the CB1 recep-
tors (Katona et al. 1999). Thus, NO originating from nNOS
in cholinergic-stimulated pyramidal cells (Szabadits et al.
2007) could serve as a retrograde regulator of the NO-
sensitive guanylyl cyclase in GABAergic interneurons
(Makara et al. 2007), such that NO in combination with
endocannabinoids could co-regulate depolarization-induced
suppression of inhibition at these GABAergic synapses
(Makara et al. 2007).
Similar to our observations of CB1 receptor-stimulated
NO production, Stefano’s laboratory demonstrated that
stimulation with anandamide led to NO production, which
inhibited depolarization-evoked dopamine release in leech
ganglia and stimulated neuropeptide release from the
mammalian median eminence (Stefano et al. 1997; Prevot
et al. 1998). Maccarrone and colleagues demonstrated that
CB1 receptor-stimulated NO production is involved in the
anandamide translocation process (Maccarrone et al. 2006).
These studies support the role of CB1 receptor-stimulated
NO production in various physiological processes.
In contrast, cannabinoid-stimulated NO production has not
been universally observed in other neuronal preparations. In
cultured rat cerebellar granule cells, depolarization-induced
Ca
2+ influx and subsequent NOS activation was reduced by
WIN55212-2 via inhibition of voltage-gated Ca
2+ channels
(Hillard et al. 1999). In this preparation, the CB1 antagonist
rimonabant augmented depolarization-induced Ca
2+ influx
and NOS activation, suggestive of competitive inhibition of
endocannabinoid (perhaps 2-arachidonoylglycerol)-mediated
autocrine stimulation of nNOS (Hillard et al. 1999). This
mechanism was very selective for voltage-gated Ca
2+
channel-regulated NOS because the NMDA receptor-
mediated Ca
2+ influx and NOS activation were not inhibited
(Hillard et al. 1999). Although the CB1 receptor can regulate
Ca
2+ channels in the N18TG2 or its progenitor NG108-15
cells (Mackie et al. 1993; Sugiura et al. 1997b), this requires
“differentiation” of the cells with cyclic AMP-generating
agents, which was not done for our studies.
Toinvestigatechroniceffectsofcannabinoids,Greenberg’s
laboratory evaluated the NO-DAF-FM fluorescence (20-min
accumulation) in cultured mouse cortical neurons after 6 h
treatment with NMDA (20 μM) in the presence or absence of
WIN55212-2 (Kim et al. 2006). WIN55212-2 abrogated the
excitotoxic NO accumulation, and either rimonabant treat-
ment or the genetic knockout of the CB1 receptor precluded
the WIN55212-2 response. Activation of PKA by dibutyryl
cAMP reversed the effects of WIN55212-2 (Kim et al.
2006), suggesting that prolonged reduction of PKA activity
by the CB1 agonist might lead to a net reduction of nNOS
phosphorylation on a key serine residue phosphorylated in
response to the NMDA stimulus. In our studies, cannabinoid
agonists would be expected to promote a pattern of
phosphorylation of nNOS that would be quite different from
that of a neuron undergoing an excitotoxic reaction in
response to NMDA (Rameau et al. 2004; Rameau et al.
2007). We determined that cannabinoid agonists stimulate a
robust and prolonged translocation of NO-sensitive guanylyl
cyclase from cytosol to the cell membranes (Jones et al.
2008). The α1β1 isoform predominantly expressed in
N18TG2 cells does not bind to the PDZ domains of
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Fig. 5 The role of Gi/o protein
on cannabinoid-mediated NO
production in N18TG2 cells.
a NO-DAF-FM fluorescence in
N18TG2 cells treated (20 min)
with 1 μM of CP55940 (CP)
(a, d), WIN55212-2 (WIN)
(b, e), or methanandamide
(MetAEA) (c, f) in the absence
(a–c) or presence (d–f)o f
pretreatment (16 h) with of
pertussis toxin (PTX; 100 ng/ml;
bar=100 μm). b Quantitation of
NO accumulation stimulated by
cannabinoid agonists (Ag) and
modulated by PTX pretreatment
is presented as the ratios of
DAF/DAPI fluorescence inten-
sity mean±SEM from N=3
independent experiments.
Significantly different from
agonist alone (*p<0.01)
J Neuroimmune Pharmacol (2009) 4:338–349 345PSD95, suggesting that the NMDA receptor and Ca
2+ influx
is not the predominant regulator of this NO effector in the
N18TG2 model.
The data obtained in our studies provide insights
regarding cellular regulation of nNOS by CB1 receptor
stimulation. Western blots using 6% or 7.5% acrylamide
gels routinely show two bands. This finding suggests that
multiple nNOS isoforms are present in the N18TG2 cell.
Post-translational phosphorylation of nNOS, which could
incorporate as many as six to seven phosphates per
monomer (Nakane et al. 1991), would result in multiple
bands that could be discerned on SDS-PAGE. PKC, Ca
2+-
calmodulin kinase II, PKA, and PKB (Akt) can regulate
nNOS activity in cells and tissues (Bredt et al. 1992;
Nakane et al. 1991; Rameau et al. 2007). Activation of
nNOS by the excitotoxic stimulation of the NMDA receptor
could be attributed to dephosphorylation of nNOS by
calcineurin and PP1/PP2A (Rameau et al. 2003; Rameau
et al. 2004). Thus, it is possible that the CB1 receptor could
stimulate NO production by a mechanism involving
phosphorylation/dephosphorylation.
An alternative explanation for the observation of two
nNOS bands on Western blots is the existence of splice
variants. Other laboratories have reported isoforms such as
the α and β forms described in mouse tissue (Brenman et
al. 1996; Brenman et al. 1997; Putzke et al. 2000). An
nNOSβ isoform lacking the 1.1 kB exon 2, which would
result in a deletion of the PDZ domain, would be expected
to be present in the cytosol but not in the membranes and
would be expected to appear as a band of >30 kDa lower
apparent MW on SDS-PAGE. Because the antibody that we
used would have recognized both forms, our data for
cytosol and membrane-associated nNOS do not support the
existence of a splice variant exhibiting these properties.
A nNOS isoform in which exons 9 and 10 are deleted and
therefore is missing the C-terminal portion of the dihydro-
folate reductase domain is a lower molecular weight dysfunc-
tional isoform that might serve a role in a cellular function
Fig. 6 The long-term regulation
of nNOS protein and gene
expression by cannabinoid
agonists in N18TG2 cells.
a Western blot analysis of
membrane and cytosol fractions
from N18TG2 cells treated with
1 μM CP55940 or WIN55212-2
for 24 h. b Densitometric
analysis of the 160 and 155 kDa
nNOS bands in membrane
(P100) and cytosolic (S100)
fractions (squares, control;
triangles, CP55940; and
inverted triangles,WIN55212-
2). The data are presented as the
mean±SEM (N=3 independent
experiments). Values signifi-
cantly different from vehicle-
treated control (*p<0.01).
c nNOS gene expression from
N18TG2 cells treated for 8 or
24 h with vehicle (Control)o r
1 μM of CP55940 (CP),
WIN55212-2 (WIN), or
methanandamide (MetAEA).
RNA was reversed transcribed
and quantified using qPCR
analysis, and relative gene
expression was compared with
control samples using the ΔΔCt
method. Data are the mean±SD
from two identical experiments
with samples run in triplicate for
each qPCR trial
346 J Neuroimmune Pharmacol (2009) 4:338–349other than NO synthesis from L-arginine (Iwasaki et al. 1999;
Ogura et al. 1993). The nNOSμ isoform, originally described
in skeletal muscle and also found in brain (Ihara et al. 2006),
possesses a 34-amino-acid insert that increases its apparent
molecular weight. It should be noted that other alternative
splicing of exons 1 and 2 can affect the untranslated region,
leading to potentially altered regulation of mRNA stability
and translation (Boissel et al. 2003; Brenman et al. 1997;
Newton et al. 2003), but would not affect the mobility on
Western blots. Studies with N18TG2 cells do not provide
convincing evidence from conventional PCR analyses that
would argue for the presence of alternative splice variants
(Lloyd and Norford, unpublished observations).
A question remains regarding the source of Ca
2+ that
triggers NO production via nNOS in the N18TG2 model.
Our studies indicate that potent CB1 agonists fail to evoke a
rise in intracellular Ca
2+ within the first few minutes of
activation. This finding contrasts with the findings of a PLC-
mediated rapid rise in intracellular Ca
2+ in neuroblastoma
cells reported by Sugiura’s laboratory (Sugiura et al. 1997a).
In contrast, Sarne’s laboratory demonstrated a slower
increase in intracellular Ca
2+ initiated by phosphorylation
of a voltage-gated L channel (Rubovitch et al. 2002), which
might coincide with the 20-min time course of NO
accumulation in our studies. Alternatively, a Ca
2+-sensing
receptor also triggers Ca
2+ mobilization in these cells (Sesay
et al. 2007). Other GPCRs such as the M2-muscarinic recep-
tor also stimulate nNOS without an obvious Ca
2+ transient
(see discussion by Chistopoulos and El Fakahany 1999).
In summary, we have found an autocrine regulation of
the CB1 receptor-nNOS-NO-sensitive guanylyl cyclase in a
model neuronal cell line. We demonstrated that, in contrast
to the NMDA-mediated nNOS stimulation by calmodulin
and modulated by Ca
2+-regulated kinases and phosphatase,
NO appears to be produced in response to CB1 receptor
stimulation in a Gi/o-selective manner without an obvious
Ca
2+ transient. Continued stimulation of NO production
results in reduction in mRNA and protein levels. Because
nNOS can be found in both membrane and cytosolic
fractions, it is possible that the CB1-mediated nNOS
activation might result entirely from kinases or phospha-
tases regulated by second messengers or by a Ca
2+ transient
occurring over a prolonged time or in response to an
alternative stimulus. Our findings help to clarify the
mechanism by which cannabinoids promote NO production
in an autocrine or paracrine signaling in biological
responses mediated by the CB1 receptor.
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